RecruitingNCT06221631
BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
Brain Aging - a Comparative Study in Healthy and Patients With Multiple Sclerosis as Model of a Chronic Neuroinflammatory Disorder (BrainAgeMS)
Sponsor
Insel Gruppe AG, University Hospital Bern
Enrollment
200 participants
Start Date
Aug 27, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to investigate new quantitative MRI-sequences for assessment of age-specific data for the prediction of brain aging.
Eligibility
Min Age: 18 YearsMax Age: 65 Years
Inclusion Criteria3
- Informed Consent signed by the subject
- Group 1: Any healthy individual between 18 and 65 years of age
- Group 2: Any individuals with any diagnosis of Multiple Sclerosis between 18 and 65 years of age and EDSS ≤6.0.
Exclusion Criteria3
- Group 1 and 2: Any other neurological disease except primary headaches: insufficient language skills in German or French; pregnancy, lactation, any contraindication for MRI (active implants, passive ferromagnetic implants, passive non-ferromagnetic metallic implants \>4cm in the region covered by the active RF coils, large tattoos inside a region covered by the active radiofrequency (RF) coils, claustrophobia or suspected/known non-compliance), smoking within the last 10 years prior recruitment, any other drug consumption except moderate alcohol intake (less than a standard drink containing 10 grams of alcohol per day) or use of medical cannabis, any previous head trauma (with known/suspected intracranial consequences), Body Mass Index (BMI) \>30, and any other chronic progressive disease.
- Specific Criteria for group 1: The calculated biological age (BioAge R Package algorithm) differs by \> -8/+1 years from the chronological age. These patients will not be further invited for a study visit with clinical examination and MRI.
- Specific Criteria for group 2: EDSS \> 6.0 as this impacts physical testing; clinical relapse within the last 6 months
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06221631
Related Trials
From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
NCT048734921 location
Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment
NCT067824641 location
Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
NCT074776392 locations
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT0381634552 locations
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
NCT072071481 location